Promising drug combo targets aggressive inflammatory breast cancer
Disease control
Recruiting now
This study tests whether two drugs, trastuzumab deruxtecan and durvalumab, can safely shrink or eliminate tumors in people with stage III inflammatory breast cancer that has a protein called HER2. About 63 participants will receive the drugs before surgery. The main goal is to se…
Phase: PHASE2 • Sponsor: Filipa Lynce, MD • Aim: Disease control
Last updated May 12, 2026 13:43 UTC